Article: Mach One Corporation Expedites Co-Development Plans with PanTheryx for Introduction of Novel Product for Treatment of Pediatric Diarrhea.

Building Foundation as a Global Supplier for Immunotherapeutic Solutions

BELGIUM, Wis. -- Mach One Corporation (OTCBB: MNCN), a rapidly growing, innovative, global wellness solutions company, announced today that it has completed the first tranche of its investment in PanTheryx, Inc., as stipulated in a recent Letter of Understanding signed in August 2009. This action expedites development and introduction plans for an orally administered antibody therapeutic for treatment of pediatric diarrhea. The co-developed pediatric diarrhea product will initially be targeted for commercial introduction in India, where PanTheryx maintains a sales force and contract sales ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!